ZPDH:F:F-SPDR S&P U.S. Health Care Select Sector UCITS (EUR)

ETF | Others |

Last Closing

USD 34.9

Change

0.00 (0.00)%

Market Cap

USD 0.40B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-25 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.55 (+1.06%)

USD 128.40B
SXR8:F iShares Core S&P 500 UCITS ETF..

+4.96 (+0.91%)

USD 114.04B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.58 (+1.02%)

USD 108.41B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.16 (+1.03%)

USD 52.77B
SXRZ:F iShares VII PLC - iShares Nikk..

+3.60 (+1.57%)

USD 52.44B
VUSA:F Vanguard Funds Public Limited ..

+0.80 (+0.82%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 46.87B
0ZC:F Zscaler Inc

+5.30 (+2.39%)

USD 37.92B
BSND:F Danone SA

N/A

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

+1.10 (+0.87%)

USD 24.77B

ETFs Containing ZPDH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.68% 9% A- 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.68% 10% F 29% F
Trailing 12 Months  
Capital Gain -13.07% 12% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.07% 11% F 32% F
Trailing 5 Years  
Capital Gain 33.51% 43% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.51% 43% F 37% F
Average Annual (5 Year Horizon)  
Capital Gain 11.53% 77% C+ 69% C-
Dividend Return 11.53% 75% C 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.32% 58% F 89% A-
Risk Adjusted Return 101.82% 92% A 93% A
Market Capitalization 0.40B 55% F 45% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike